Aquestive Therapeutics, Inc. Receivables, Net, Current
Aquestive Therapeutics, Inc. (AQST) had Receivables, Net, Current of $9.33 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:ReceivablesNetCurrent · last filed 2026-08-11
- 2026-06-30: Receivables, Net, Current $9.33M.
- 2026-03-31: Receivables, Net, Current $6.87M.
- 2025-12-31: Receivables, Net, Current $17.76M.
- 2024-12-31: Receivables, Net, Current $7.34M.
| Period end | Receivables, Net, Current |
|---|---|
| 2026-06-30 | $9.33M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $6.87M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $17.76M 10-Q · filed 2026-08-11 |
| 2024-12-31 | $7.34M 10-K · filed 2026-03-04 |
| 2023-12-31 | $8.47M 10-K · filed 2025-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |